menu
    • menu
    [{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Oral Presentation Of Phase 1 Data For 4-1bb\/Her2 Bispecific Prs-343 At ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pieris and Lilly Ink Clinical Trial Collaboration to Evaluate Combination of Prs-343 with Ramucirumab and Paclitaxel In Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts Partial Clinical Hold Pieris Pharmaceuticals' Prs-343 Phase 1 Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"PRS-343","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Seagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pieris Announces Amendment of Existing Collaboration with Seagen to Evaluate Cinrebafusp Alfa in Combination with Tukysa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Cinrebafusp alfa","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pieris Pharmaceuticals \/ Pieris Pharmaceuticals"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","amount":"$363.0 million","upfrontCash":"$10.0 million","newsHeadline":"Pieris Pharmaceuticals and Boston Pharmaceuticals Ink Exclusive Worldwide Product License for PRS-342","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"PRS-342","moa":"4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pieris Pharmaceuticals","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Pieris Pharmaceuticals \/ Boston Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pieris Pharmaceuticals \/ Boston Pharmaceuticals"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060\/AZD1402)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Elarekibep","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060\/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Elarekibep","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals by Pieris Pharmaceuticals

    Menu

    Pieris Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elarekibep

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)...

                            Details : PRS-060/AZD-1402 (elarekibep) is Pieris’ lead respiratory Anticalin®-based drug candidate and an inhaled IL-4 receptor alpha inhibitor, under development for the treatment of asthma.

                            Brand Name : PRS-060

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 21, 2023

                            Lead Product(s) : Elarekibep

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elarekibep

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of El...

                            Details : PRS-060 (elarekibep) blocks the IL-4Ralpha immunoreceptor, inhibiting small IL-4 and IL-13 proteins that drive a cascade of inflammatory responses in the lungs. It is being developed for the treatment of moderate-to-severe asthma.

                            Brand Name : PRS-060

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 04, 2023

                            Lead Product(s) : Elarekibep

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRS-342

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Boston Pharmaceuticals

                            Deal Size : $363.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pieris Pharmaceuticals and Boston Pharmaceuticals Ink Exclusive Worldwide Product License for PRS-342

                            Details : Under the terms of the agreement, Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342. Boston Pharmaceuticals will be primarily responsible for development of the program, with both parties collaborating during the IND-enabling st...

                            Brand Name : PRS-342

                            Molecule Type : Large molecule

                            Upfront Cash : $10.0 million

                            April 26, 2021

                            Lead Product(s) : PRS-342

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Boston Pharmaceuticals

                            Deal Size : $363.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cinrebafusp alfa,Tucatinib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Seagen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pieris Announces Amendment of Existing Collaboration with Seagen to Evaluate Cinrebafusp Alfa in Combination w...

                            Details : Pieris' option to co-develop and co-commercialize the second of 3 programs in the collaboration has been amended to provide it with a co-promotion option in the U.S, with Seagen solely responsible for the development and overall commercialization of that...

                            Brand Name : PRS-343

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 25, 2021

                            Lead Product(s) : Cinrebafusp alfa,Tucatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Seagen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRS-343

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Lifts Partial Clinical Hold Pieris Pharmaceuticals' Prs-343 Phase 1 Studies

                            Details : U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.

                            Brand Name : PRS-343

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 19, 2021

                            Lead Product(s) : PRS-343

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRS-343,Ramucirumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pieris and Lilly Ink Clinical Trial Collaboration to Evaluate Combination of Prs-343 with Ramucirumab and Pacl...

                            Details : Lilly to supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this y...

                            Brand Name : PRS-343

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 10, 2020

                            Lead Product(s) : PRS-343,Ramucirumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRS-343,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pieris Pharmaceuticals Announces Oral Presentation Of Phase 1 Data For 4-1bb/Her2 Bispecific Prs-343 At ESMO V...

                            Details : Company will present phase 1 dose-escalation monotherapy and combination with atezolizumab data for PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in an oral presentation session at the European Society for Medical Onco...

                            Brand Name : PRS-343

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 23, 2020

                            Lead Product(s) : PRS-343,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Pieris Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRS-343,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343

                            Details : The partial hold follows discussions with FDA regarding the Company's in-use study supporting the technical setup for clinical administration of PRS-343.

                            Brand Name : PRS-343

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 20, 2020

                            Lead Product(s) : PRS-343,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth